Austin, TX 11/29/2007 12:10:27 AM
Speak with other shareholders about: (OTC: AWTM), (NYSE: CI), (NYSE: THC), (NYSE: UNH), (AMEX: INO)
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the Chat Live button at the top.
----------------------------------------------------------
Chat real-time with other investors about this AWTM news release,
by clicking this link: http://www.stockwire.com/AWTM
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=AWTM
Nov. 27, 2007 -- AWT, Inc. (OTC: AWTM), announced that it signed agreements that will facilitate its acquisition of a local medical supply and medical equipment distribution company. The Standstill Agreement allows for AWT and its acquisition partner to continue with business as usual and complete the necessary documents for the closing of the transaction and the financing earlier announced. "A Standstill Agreement, as both of our companies have agreed, is mutually binding in the fact that we do not go around each other to clients and we do not shop the terms of this deal to rivals. It gives both companies the ability to complete and close the transaction," commented Christopher J. Neill, AWT's CEO. Furthering his comment, "Both companies are interested in a smooth transition to a larger organization and resourceful expansion."
----------------------------------------------------------
Chat real-time with other investors about this CI news release,
by clicking this link: http://www.stockwire.com/CI
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=CI
Nov. 27, 2007 -- Cigna Corp.'s (NYSE: CI) planned acquisition of Great-West Healthcare appears to be a smart move that will expand the health insurer's reach and deliver a host of efficiencies, analysts said on Tuesday. Cigna, whose shares were up 1.4 percent, said late on Monday that it would buy the U.S. health-care division of Great-West Lifeco Inc. for $1.5 billion. Cigna also plans to inject about $400 million into the business. The deal will grow Cigna's medical enrollment by 1.5 million and is expected to boost the company's earnings beginning next year. Cigna will gain about 660,000 members, which Great-West had through third-party administrators.
----------------------------------------------------------
Chat real-time with other investors about this THC news release,
by clicking this link: http://www.stockwire.com/THC
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=THC
Nov. 27, 2007 -- Hospital operator Tenet Healthcare Corp. (NYSE: THC) said Tuesday that it signed a two-year national contract with health insurer UnitedHealth Group (NYSE: UNH). Financial details were not disclosed. The deal gives UnitedHealthcare members, part of UnitedHealth Group, access to acute care in Tenet's hospitals. Tenet also has a current contract with health insurer Aetna Inc.
----------------------------------------------------------
Chat real-time with other investors about this INO news release,
by clicking this link: http://www.stockwire.com/INO
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=INO
Nov. 27, 2007 -- Inovio Biomedical Corporation (AMEX: INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced that its partner, Tripep AB of Sweden, treated the first subject in a Phase I/II clinical trial of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The clinical trial is designed to test Tripep's proprietary DNA vaccine, ChronVac-C , administered using Inovio's MedPulser DNA Delivery System, in 12 subjects already infected with HCV. The trial is being conducted in Sweden at two Karolinska University Hospitals, the Center for Gastroenterology in Solana and at the Infections Clinic in Huddinge.
--------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the National Association of Securities Dealers (NASDAQ) at www.NASDAQ.com. The NASDAQ has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We often receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares into the open market.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
